464 related articles for article (PubMed ID: 8381186)
1. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacology of camptothecin and its derivatives].
Rivory LP; Robert J
Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of camptothecin.
Liu LF; Desai SD; Li TK; Mao Y; Sun M; Sim SP
Ann N Y Acad Sci; 2000; 922():1-10. PubMed ID: 11193884
[TBL] [Abstract][Full Text] [Related]
5. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
6. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
7. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
8. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Kaufmann SH
Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
[TBL] [Abstract][Full Text] [Related]
9. Camptothecin analogues in the treatment of non-small cell lung cancer.
Ardizzoni A
Lung Cancer; 1995 Apr; 12 Suppl 1():S177-85. PubMed ID: 7551927
[TBL] [Abstract][Full Text] [Related]
10. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
Int J Cancer; 1992 Mar; 50(5):760-6. PubMed ID: 1312063
[TBL] [Abstract][Full Text] [Related]
11. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
[TBL] [Abstract][Full Text] [Related]
12. Determinants of drug response in camptothecin-11-resistant glioma cell lines.
Matsumoto Y; Fujiwara T; Nagao S
J Neurooncol; 1995; 23(1):1-8. PubMed ID: 7623066
[TBL] [Abstract][Full Text] [Related]
13. Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes.
Gokduman K
Curr Drug Targets; 2016; 17(16):1928-1939. PubMed ID: 27138759
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
[TBL] [Abstract][Full Text] [Related]
16. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Kaufmann SH; Svingen PA; Gore SD; Armstrong DK; Cheng YC; Rowinsky EK
Blood; 1997 Mar; 89(6):2098-104. PubMed ID: 9058732
[TBL] [Abstract][Full Text] [Related]
17. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
19. [Topoisomerase inhibitors developing in Japan].
Furue H
Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
[TBL] [Abstract][Full Text] [Related]
20. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
